Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBI3040
- Development stage
- Phase 1
- Lead developer
- Innovent Biologics
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
IBI3040 is a novel amylin analog being developed by Innovent Biologics for the treatment of obesity and metabolic diseases. As a biologic targeting the amylin pathway, it has demonstrated superior weight loss in preclinical models compared to existing therapies. It is part of Innovent's next-generation obesity and metabolic disease pipeline, which is designed to address unmet needs regarding tolerability, muscle preservation, dosing convenience, durability of weight loss, and management of obesity-related comorbidities. Preclinical data for IBI3040 was presented at the 2026 American Diabetes Association (ADA) Scientific Sessions.
02
Targets
AMY receptor (Calcitonin receptor (with ramps))
Beyond the preview
Go deeper on IBI3040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBI3040.